Before talking about best practices for visually presenting scientific data, it is important to summarize and define what tools are available. For most fields, graphs are the most common form of ...

Ernexa’s recent update on operational excellence enables the company to allocate valuable resources where they are needed most: advancing ERNA-101 into clinical trials. The data that Dr. Andreeff is ...

Preliminary results from a pooled analysis of clinical trial data evaluating the long-term safety and favorable benefit-risk profile of WINREVAIR™ to be featured as a late-breaking presentation RAHWAY ...

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and ...

MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer ...

BOSTON, March 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients ...

Circle Pharma, a clinical-stage biopharmaceutical company focused on developing cell-permeable macrocycle therapeutics, today announced a late-breaking poster presentation at the American Association ...

Circle Pharma to Present Late-Breaking Data at AACR 2025 Demonstrating Mechanism of Action for Novel Cyclin A/B RxL Inhibitors Circle Pharma, a clinical-stage biopharmaceutical company focused on ...

BioRestorative Therapies, Inc. announced that it will present new blinded safety and efficacy data from its Phase 2 trial of BRTX-100 for chronic lumbar disc disease (cLDD) at the ISSCR 2025 Annual ...

Title : MET-233 is a differentiated efficacious amylin analogue in preclinical studies, combinable with MET-097, an ultra-long acting GLP-1 receptor agonist​ (224) Presentation type: Oral presentation ...